Full-Time

Counsel – Gxp Compliance

Posted on 5/9/2025

Viatris

Viatris

10,001+ employees

Global healthcare company providing medicines access

Compensation Overview

$151k - $314k/yr

Senior, Expert

Remote in USA

Candidates must be based in the United States.

Category
Legal
Risk & Compliance
Legal & Compliance
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Viatris referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Juris Doctorate is required
  • 7 years of experience in Pharmaceutical or biotechnology industry as inside or outside counsel
  • Seven years of Legal experience advising clients directly or under the supervision of lawyers
  • Licensed to practice law in one or more jurisdictions is required
  • Exceptional oral and written communication skills, including strong presentation capabilities
  • Strong interpersonal and conflict resolution skills
  • Ability to work in a collaborative, team-oriented environment
  • Proficiency in speaking, comprehending, reading and writing English is required
Responsibilities
  • Responsible for counseling clients on a wide range of issues with focus on GxP and Quality processes for the development, manufacture, and distribution of drugs, biologics, medical devices, supplements, and cosmetics
  • Provide timely and effective counsel related to compliance with GxP regulations from various health authorities (e.g., FDA, EMA, TGA, Health Canada, WHO)
  • Assist with development of corrective action plans and responses following regulatory inspections and inquiries
  • Assist in developing materials for regulatory meetings and preparing teams participating in such meetings
  • Participate in committee meetings to review internal quality metrics and participate in site or project governance committees, as needed
  • Provide guidance on product quality incidents and post-marketing reporting obligations and actions
  • Work cross functionally with Quality, Regulatory, and other stakeholders to advise on and support process and systems improvements, including development of global quality policies and training materials
  • Prepare and edit written reports and communications for internal and external use related to regulatory and GxP compliance requirements and obligations
  • Monitor the external environment and advise teams on policy and regulatory developments related to GxP and related activities
  • Manage engagements with outside counsel to ensure effective and efficient use
  • Perform related duties as assigned
Desired Qualifications
  • Three to five years of technical expertise in manufacturing and GxP auditing preferred
  • Background/education in science related discipline is preferred

Viatris is a global healthcare company that combines generic and brand-name medicines to meet healthcare needs worldwide. The company provides access to high-quality medicines, having supplied them to around 1 billion patients in 2022. Viatris has a diverse portfolio of medicines and a global supply chain that ensures they reach people when and where they need them. This allows Viatris to address a wide range of health challenges, from acute conditions to chronic diseases, impacting all stages of life. Unlike many competitors, Viatris focuses on bridging the gap between generics and brands, aiming to empower individuals to live healthier lives. The company's goal is to enhance access to healthcare for people globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Viatris can leverage digital health trends to expand telemedicine and remote monitoring services.
  • The rise of value-based healthcare aligns with Viatris' focus on patient outcomes and cost-effectiveness.
  • Expansion in emerging markets offers Viatris opportunities to increase market presence and reach.

What critics are saying

  • Increased competition from low-cost generics could erode Viatris' market share.
  • Patent expirations in 2025 may lead to revenue loss from generic competition.
  • Ongoing opioid litigation could result in financial liabilities and reputational damage.

What makes Viatris unique

  • Viatris bridges the gap between generics and brands, offering a unique healthcare approach.
  • The company has a diverse portfolio, supplying medicines to 1 billion patients annually.
  • Viatris' global supply chain is designed to reach patients worldwide efficiently.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

PharmiWeb
May 7th, 2025
Viatris Announces Quarterly Dividend

PITTSBURGH, May 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025, to shareholders of record as of the close of business on May 23, 2025.About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris

PR Newswire
Mar 28th, 2025
Viatris To Report First Quarter 2025 Financial Results On May 8, 2025

PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 27th, 2025
Viatris Maintains Dividend Policy For 2025 And Announces Quarterly Dividend

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally